JP6689854B2 - Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 - Google Patents

Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 Download PDF

Info

Publication number
JP6689854B2
JP6689854B2 JP2017529350A JP2017529350A JP6689854B2 JP 6689854 B2 JP6689854 B2 JP 6689854B2 JP 2017529350 A JP2017529350 A JP 2017529350A JP 2017529350 A JP2017529350 A JP 2017529350A JP 6689854 B2 JP6689854 B2 JP 6689854B2
Authority
JP
Japan
Prior art keywords
compound
cells
groups
composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017529350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536395A5 (enExample
JP2017536395A (ja
Inventor
ジョン エル． マグナニ，
ジョン エル． マグナニ，
アルン ケー． サーカー，
アルン ケー． サーカー，
ジョン エム． ピーターソン，
ジョン エム． ピーターソン，
Original Assignee
グリコミメティクス， インコーポレイテッド
グリコミメティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコミメティクス， インコーポレイテッド, グリコミメティクス， インコーポレイテッド filed Critical グリコミメティクス， インコーポレイテッド
Publication of JP2017536395A publication Critical patent/JP2017536395A/ja
Publication of JP2017536395A5 publication Critical patent/JP2017536395A5/ja
Application granted granted Critical
Publication of JP6689854B2 publication Critical patent/JP6689854B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017529350A 2014-12-03 2015-12-01 Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 Expired - Fee Related JP6689854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087085P 2014-12-03 2014-12-03
US62/087,085 2014-12-03
PCT/US2015/063191 WO2016089872A1 (en) 2014-12-03 2015-12-01 Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020044383A Division JP2020090553A (ja) 2014-12-03 2020-03-13 Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤

Publications (3)

Publication Number Publication Date
JP2017536395A JP2017536395A (ja) 2017-12-07
JP2017536395A5 JP2017536395A5 (enExample) 2018-11-22
JP6689854B2 true JP6689854B2 (ja) 2020-04-28

Family

ID=56092327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017529350A Expired - Fee Related JP6689854B2 (ja) 2014-12-03 2015-12-01 Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
JP2020044383A Withdrawn JP2020090553A (ja) 2014-12-03 2020-03-13 Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020044383A Withdrawn JP2020090553A (ja) 2014-12-03 2020-03-13 Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤

Country Status (16)

Country Link
US (1) US10519181B2 (enExample)
EP (2) EP3227310B1 (enExample)
JP (2) JP6689854B2 (enExample)
KR (1) KR102542750B1 (enExample)
CN (1) CN107108679B (enExample)
AU (1) AU2015355136B2 (enExample)
CA (1) CA2968391C (enExample)
CY (1) CY1122038T1 (enExample)
DK (1) DK3227310T3 (enExample)
ES (1) ES2754549T3 (enExample)
HU (1) HUE045542T2 (enExample)
LT (1) LT3227310T (enExample)
PL (1) PL3227310T3 (enExample)
PT (1) PT3227310T (enExample)
SI (1) SI3227310T1 (enExample)
WO (1) WO2016089872A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3227310T (pt) 2014-12-03 2019-11-06 Glycomimetics Inc Inibidores heterobifuncionais de e-selectinas e recetores de quimiocina cxcr4
JP6958820B2 (ja) 2015-12-14 2021-11-02 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN109890421B (zh) 2016-10-07 2023-10-20 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
JP7275131B2 (ja) * 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko) * 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
CA3091454A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
WO2020123435A2 (en) 2018-12-10 2020-06-18 Glycomimetics, Inc. Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020150263A1 (en) 2019-01-14 2020-07-23 Magnani John L Selectin or galectin antagonists for treating cytokine release syndrome and crs-induced neurotoxicity
JP2022529806A (ja) 2019-04-24 2022-06-24 グリコミメティクス， インコーポレイテッド Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤
WO2021011435A1 (en) 2019-07-12 2021-01-21 Magnani John L Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
EP4003367B1 (en) * 2019-07-31 2025-12-24 Crescent Biopharma, Inc. E-selectin antagonists for use in enhancing the survival of reconstituted, bone marrow-depleted hosts
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
WO2021195465A1 (en) * 2020-03-27 2021-09-30 Magnani John L Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
EP4157285A1 (en) 2020-05-31 2023-04-05 GlycoMimetics, Inc. Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis
US20230218649A1 (en) 2020-06-14 2023-07-13 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
WO2023014690A1 (en) 2021-08-03 2023-02-09 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7409399A (nl) 1973-07-19 1975-01-21 Rhone Poulenc Sa Werkwijze ter bereiding van thermostabiele har- sen en voorwerpen geheel of gedeeltelijk be- staande uit deze harsen.
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
DK17885D0 (da) 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US4876199A (en) 1985-04-04 1989-10-24 Fred Hutchinson Cancer Research Center Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain
US4851511A (en) 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
DE3787403D1 (de) 1986-05-09 1993-10-21 Pulverer Gerhard Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
EP0381310A1 (en) 1989-01-30 1990-08-08 The Biomembrane Institute Monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides and method for production thereof
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
DE69021456T2 (de) 1989-05-23 1996-02-15 Otsuka Pharma Co Ltd Monoklonale Antikörper gegen aktivierte endotheliale Zellen.
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
WO1991019501A1 (en) 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
ATE224911T1 (de) 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
US5648344A (en) 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5143712A (en) 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5211937A (en) 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
NZ240316A (en) 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
AU656934B2 (en) 1990-11-23 1995-02-23 General Hospital Corporation, The Inhibition of cell adhesion protein-carbohydrate interactions
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
AU660995B2 (en) 1991-05-06 1995-07-13 Genentech Inc. Glycam-1 (Sgp 50), a selectin ligand
US5318890A (en) 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US5646123A (en) 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5580858A (en) 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
CA2118695A1 (en) 1991-09-10 1993-03-18 George A. Heavner Peptide inhibitors of inflammation mediated by selectins
US5268364A (en) 1991-12-12 1993-12-07 The Biomembrane Institute Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification
JPH07501828A (ja) 1991-12-18 1995-02-23 セントコー，インコーポレイテッド セレクチン類で仲介される炎症のペプチド阻害剤
US5643873A (en) 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5591835A (en) 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
CA2100412A1 (en) 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
CA2144180A1 (en) 1992-09-08 1994-03-17 George A. Heavner Peptide inhibitors of cellular adhesion
US5519008A (en) 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
WO1994006442A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5710123A (en) 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
DE69322289T2 (de) 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US5412123A (en) 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
JP2716657B2 (ja) 1993-02-26 1998-02-18 株式会社ディ・ディ・エス研究所 接着分子ｅｌａｍ‐１に特異的結合能を有する化合物
WO1994020514A1 (fr) 1993-03-04 1994-09-15 Mect Corporation Compose associe au systeme de lewis, procede d'obtention de ce compose et anti-inflammatoire
US5527890A (en) 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
EP0700301B1 (en) 1993-05-05 1999-09-01 Affymax Technologies N.V. Peptides and compounds that bind to elam-1
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
SE9301677L (sv) 1993-05-14 1994-11-18 Kurt G I Nilsson Syntesmetod
CN1125449A (zh) 1993-05-14 1996-06-26 萨依特尔有限公司 作为细胞粘附抑制剂的唾液基Lex类似物
US5854218A (en) 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
WO1994026786A1 (en) 1993-05-17 1994-11-24 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5646248A (en) 1993-06-08 1997-07-08 La Jolla Cancer Research Foundation E-selection binding soluble lamp-1 polypeptide
US5837689A (en) 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5750508A (en) 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5658880A (en) 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5789385A (en) 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5679321A (en) 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
DK76193D0 (da) 1993-06-25 1993-06-25 Astra Ab Kulhydratderivater
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5508387A (en) 1993-08-04 1996-04-16 Glycomed Incorporated Selectin binding glycopeptides
WO1995005830A1 (en) 1993-08-20 1995-03-02 The Regents Of The University Of California Polyanion anti-inflammatory agents
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
WO1995010296A1 (en) 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5663151A (en) 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
DE4408248A1 (de) 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
EP0671409A3 (de) 1994-03-11 1996-06-12 Hoechst Ag Malonsäurederivate mit antiadhäsiven Eigenschaften.
HUT77345A (hu) 1994-04-29 1998-03-30 Texas Biotechnology Corporation E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
US5486536A (en) 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
JPH0899989A (ja) 1994-09-30 1996-04-16 Akira Hasegawa 新規糖脂質誘導体およびその製造用中間体
DE4436164A1 (de) 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5639734A (en) 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
MX9704893A (es) 1994-12-28 1997-10-31 Sumitomo Pharma Derivados de lewis x y procesos para producir los mismos.
US20020040008A1 (en) 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5527936A (en) 1995-02-17 1996-06-18 E. I. Du Pont De Nemours And Company Hydrosilylation of unsaturated compounds
GB9504065D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
AU6155896A (en) 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
AU704596B2 (en) 1995-06-29 1999-04-29 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
PL324258A1 (en) 1995-06-29 1998-05-11 Ciba Geigy Ag Diglycosiled 1,2-dioles mimetisingly acting on sialed lewis x and sialed lewis a
US5876715A (en) 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
DE19532902A1 (de) 1995-09-06 1997-03-13 Hoechst Ag Neuartige Glycomimetika als Selektin-Antagonisten und daraus hergestellte entzündungshemmend wirkende Arzneimittel
DE19537334A1 (de) 1995-10-09 1997-04-10 Hoechst Ag Antiadhäsive Piperidin- und Pyrrolidin-Carbonsäuren
AU7445796A (en) 1995-10-18 1997-05-07 Cytel Corporation Sialyl lex analogues as inhibitors of cellular adhesion
WO1997015585A1 (en) 1995-10-26 1997-05-01 Kanebo, Ltd. Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
US5747463A (en) 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
JPH09176047A (ja) 1995-12-25 1997-07-08 Unitika Ltd 外用医薬製剤
DE19602355A1 (de) 1996-01-24 1997-07-31 Hoechst Ag Mehrfach fucosylierte Dicarbonsäuren mit antiadhäsiven Eigenschaften
US6187754B1 (en) 1996-01-30 2001-02-13 Glycotech Corp. Sialyl-Lewisa and sialyl-Lewisx epitode analogues
EP0886640B1 (en) 1996-01-30 2007-03-21 GlycoMimetics, Inc. SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU718317B2 (en) 1996-03-01 2000-04-13 Regents Of The University Of California, The Inhibition of selectin binding
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5654412A (en) 1996-05-29 1997-08-05 Glycomed Incorporated Processes for the synthesis of sialyl Lewisx compounds
CA2197058A1 (en) 1996-06-05 1997-12-06 Avery B. Nathens Anti-inflammatory agent
US5919768A (en) 1996-06-26 1999-07-06 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
NZ334048A (en) 1996-08-08 2000-05-26 Novartis Ag Mimetics of natural carbohydrate epitotes as ligands for E and P Selectin
US5830871A (en) 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
GB9618520D0 (en) 1996-09-05 1996-10-16 Chiroscience Ltd Compounds and their therapeutic use
US6592872B1 (en) 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
EP1829550A3 (en) 1996-09-27 2008-04-30 The Trustees of Columbia University in the City of New York Methods for treating an ischemic disorder and improving stroke outcome
US6110897A (en) 1996-10-10 2000-08-29 Glycorex Ab Antiinflammatory cell adhesion inhibitors
US6043348A (en) 1996-11-13 2000-03-28 Lawman; Michael J. P. Antibody recognizing a small subset of human hematopoietic cells
EP1019064A4 (en) 1997-02-28 2006-11-08 Univ California Inhibition of cell-cell binding by lipid assemblies
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
SE9701127D0 (sv) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes
JP3720520B2 (ja) 1997-03-27 2005-11-30 タカラバイオ株式会社 糖と標的物との相互作用の測定方法
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6193973B1 (en) 1997-08-22 2001-02-27 B. David Tuttle Dietary supplement for boosting energy and increasing muscular strength
US5948628A (en) 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999043356A1 (en) 1998-02-25 1999-09-02 Hsc Research Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US6458777B1 (en) 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US6037333A (en) 1998-05-07 2000-03-14 Trustees Of Tufts College Microbe-inhibiting compositions
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
DE69934890D1 (de) 1998-06-16 2007-03-08 Univ Oklahoma Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
WO2000017216A1 (fr) 1998-09-21 2000-03-30 Otsuka Pharmaceutical Co., Ltd. Derives de carboxymethylgalactose
US6960566B1 (en) 1998-11-06 2005-11-01 The Wister Institute of Anatomy and Biology Compositions and methods for treatment of cancer
WO2000029029A1 (en) 1998-11-12 2000-05-25 Novolytics Inc. Compositions and methods for producing vascular occlusion
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4692400A (en) * 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US20020031508A1 (en) 2000-05-19 2002-03-14 Wagner Denisa D. Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
US20020165178A1 (en) 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
AU2000274809A1 (en) 2000-09-12 2002-03-26 Genetics Institute Llc Inhibition of stenosis or restenosis by p-selectin antagonists
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2428721A1 (en) 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
JP4262480B2 (ja) 2000-11-29 2009-05-13 ブラッコ インターナショナル ビー．ヴイ． 結合能を有するシアリル・ルイスｘ類似物
US20020132220A1 (en) 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
JP2005512505A (ja) 2001-03-28 2005-05-12 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 外因性タンパク質をサイトゾルに運搬する方法およびその使用
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7087212B2 (en) 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
WO2003032925A2 (en) 2001-10-19 2003-04-24 Cummings Richard D Glycosulfopeptide inhibitors and methods of use thereof
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
RU2325387C2 (ru) 2001-12-21 2008-05-27 Анормед Инк. Гетероциклические соединения с повышенной эффективностью, связывающиеся с рецептором хемокина
US20030186942A1 (en) 2002-01-16 2003-10-02 Crooks Peter A. Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
WO2003088980A1 (en) 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
EP1539251A4 (en) 2002-07-03 2009-02-25 Glycomimetics Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL DISEASES WITH ANGIOGENESIS
AU2003282821B2 (en) 2002-10-11 2010-12-16 University Of Maryland, Baltimore Carbohydrate-based synthetic vaccines for HIV
AU2003301209A1 (en) 2002-12-20 2004-07-22 Glycomimetics, Inc. Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection
US6844125B2 (en) 2003-03-20 2005-01-18 Kabushiki Kaisha Toshiba Combination of developing agents, image forming apparatus, and method for forming image
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20040219158A1 (en) 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US7041226B2 (en) 2003-11-04 2006-05-09 Lexmark International, Inc. Methods for improving flow through fluidic channels
WO2005046597A2 (en) 2003-11-07 2005-05-26 Brigham And Womens's Hospital, Inc. Antibodies to cd44 glycoforms and uses thereof
WO2005054264A2 (en) 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
WO2005051920A2 (en) 2003-11-19 2005-06-09 Glycomimetics, Inc. Specific antagonist for both e- and p-selectins
CA2549074A1 (en) 2003-12-18 2005-06-30 Unibioscreen S.A. Glycosylated steroid derivatives with anti-migratory activity
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
US7745421B2 (en) 2004-05-25 2010-06-29 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
CA2571431A1 (en) 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers
WO2006017180A2 (en) 2004-07-09 2006-02-16 Progenics Pharmaceuticals, Inc. Glycopeptide dimers and uses thereof
EP1790639B1 (en) 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclic compounds and their use as cxcr4-antagonists
WO2006062946A2 (en) 2004-12-06 2006-06-15 University Of Florida Research Foundation, Inc. Incorporation of bone marrow derived stem cells in tumors
EP1838320B1 (en) 2005-01-07 2014-07-16 Emory University Cxcr4 antagonists for the treatment of medical disorders
AP2007004095A0 (en) 2005-01-07 2007-08-31 Univ Emory Cxcr4 antagonists for the treatment of hiv infection
WO2006089106A2 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
US20090036386A1 (en) 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
US20060287253A1 (en) 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
CA2616166A1 (en) 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compositions and selectin inhibition
AU2006280101B2 (en) 2005-08-09 2012-06-28 Glycomimetics, Inc. Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
AU2006279736A1 (en) 2005-08-15 2007-02-22 The Scripps Research Institute Methods to identify therapeutic agents useful for treating and preventing atherosclerosis by counteracting the effect of cholesterol ozonation products
WO2007022385A2 (en) 2005-08-18 2007-02-22 Novartis Ag Use of cxcr4 binding molecules for the treatment of whim syndrome
PT1934236E (pt) 2005-09-02 2012-12-26 Glycomimetics Inc Inibidores de pan-selectina heterobifuncionais
US20090117154A1 (en) 2005-09-14 2009-05-07 University Of Maryland Biotechnolgy Institute Synthetic polyvalent carbohydrates as components of microbicides
WO2007143052A1 (en) 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP2029164B1 (en) 2006-06-07 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
WO2008002449A2 (en) 2006-06-23 2008-01-03 Glycomimetics, Inc. Glycomimetic inhibitors of siglec-8
WO2008008852A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
EP2041067A4 (en) 2006-07-11 2009-11-25 Univ Emory CXER4 ANTAGONISTS WITH DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL PROBLEMS
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
US7998740B2 (en) 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
CA2666103C (en) 2006-10-12 2014-02-18 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
US20080306098A1 (en) 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2008087259A1 (en) 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
EP2457573A1 (en) 2007-02-09 2012-05-30 GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines
US20080261978A1 (en) 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
US20090054334A1 (en) 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
CN101848991A (zh) 2007-08-08 2010-09-29 协和发酵麒麟株式会社 分离的细胞群
AU2008310664A1 (en) 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
FI20070853A0 (fi) 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
WO2009073911A1 (en) 2007-12-10 2009-06-18 Mater Medical Research Institute Treatment and prophylaxis
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2009152245A1 (en) 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
WO2010025416A1 (en) * 2008-08-29 2010-03-04 Genzyme Corporation Cxcr4 antagonists for kidney injury
US20100240773A1 (en) 2009-03-23 2010-09-23 Kenneth Korzekwa Multifunctional linkers
FI20095459A0 (fi) 2009-04-24 2009-04-24 Suomen Punainen Risti Veripalv Uusia määritysmenetelmiä
EP2424544A1 (en) 2009-05-01 2012-03-07 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US20120093782A1 (en) 2009-05-13 2012-04-19 Grove Robert I Enhanced Hematopoietic Stem Cell Engraftment
AU2011237629B2 (en) 2010-04-07 2015-09-17 Glycomimetics, Inc. Glycomimetic compounds and methods to inhibit infection by HIV
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
US20130261070A1 (en) 2010-10-04 2013-10-03 John L. Magnani Anti-epileptogenic agents
FI20106031A0 (fi) 2010-10-06 2010-10-06 Suomen Punainen Risti Veripalv Menetelmä solujen eristämiseksi ja menetelmällä eristetty solupopulaatio
WO2012061662A1 (en) 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
WO2012151576A1 (en) 2011-05-05 2012-11-08 Robert Sackstein Methods of treating complications and disorders associated with g-csf administration
DK2794626T6 (da) 2011-12-22 2020-08-24 Glycomimetics Inc E-selectin-antagonistforbindelser
CA2888527A1 (en) 2012-10-31 2014-05-08 Glycomimetics, Inc. E-selectin antagonists compounds and methods of use
PL2928476T3 (pl) 2012-12-07 2018-07-31 Glycomimetics, Inc. Związki, kompozycje i sposoby wykorzystujące antagonistów e-selektyny do mobilizacji komórek hematopoietycznych
WO2014149837A1 (en) 2013-03-15 2014-09-25 Glycomimetics, Inc. Compounds and methods to enhance the oral availability of glycomimetics
AU2014324634A1 (en) 2013-09-30 2016-04-14 Glycomimetics, Inc. Methods and compositions for treating and/or preventing mucositis
WO2015109049A1 (en) 2014-01-17 2015-07-23 Glycomimetics, Inc. E-selectin antagonists modified by macrocycle formation to the galactose
PT3227310T (pt) 2014-12-03 2019-11-06 Glycomimetics Inc Inibidores heterobifuncionais de e-selectinas e recetores de quimiocina cxcr4
WO2016164394A1 (en) 2015-04-08 2016-10-13 Glycomimetics, Inc. 2-halo-galactose-containing selectin antagonists
WO2017095904A1 (en) 2015-12-02 2017-06-08 Glycomimetics, Inc. Heterobifunctional pan-selectin antagonists having a triazole linker

Also Published As

Publication number Publication date
PL3227310T3 (pl) 2020-02-28
KR102542750B1 (ko) 2023-06-12
ES2754549T3 (es) 2020-04-20
BR112017011446A2 (pt) 2018-02-27
LT3227310T (lt) 2019-09-10
CN107108679A (zh) 2017-08-29
WO2016089872A1 (en) 2016-06-09
US10519181B2 (en) 2019-12-31
KR20170085594A (ko) 2017-07-24
CA2968391C (en) 2022-04-26
CY1122038T1 (el) 2020-10-14
EP3569609A1 (en) 2019-11-20
EP3227310A4 (en) 2018-07-25
AU2015355136A1 (en) 2017-06-08
PT3227310T (pt) 2019-11-06
CA2968391A1 (en) 2016-06-09
CN107108679B (zh) 2020-10-23
NZ732034A (en) 2022-03-25
SI3227310T1 (sl) 2019-11-29
AU2015355136B2 (en) 2020-06-25
JP2017536395A (ja) 2017-12-07
HUE045542T2 (hu) 2019-12-30
EP3227310B1 (en) 2019-07-31
DK3227310T3 (da) 2019-09-30
JP2020090553A (ja) 2020-06-11
US20170305951A1 (en) 2017-10-26
EP3227310A1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
JP6689854B2 (ja) Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
AU2023204344A1 (en) Highly potent multimeric E-selectin antagonists
CA2891514C (en) Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
JP2016531871A (ja) 粘膜炎を治療および／または予防するための方法および組成物
US20150284420A1 (en) E-selectin antagonist compounds and methods of use
US20230134986A1 (en) Glucose triptolide conjugates and uses thereof
KR20150041786A (ko) 암치료 및 면역억제를 위한 조합요법
CN114269747A (zh) 一种1’,2’-二氢-3’h-螺[环丁烷1,4’-异喹啉]-3’-酮衍生物及其应用
WO2020135569A1 (zh) 乙二胺类化合物及其用途
CN109602734A (zh) 用于治疗白血病的化合物和方法
CN112513000A (zh) 新型联苯衍生物化合物及其用途
US6716879B2 (en) Methods for anti-tumor therapy
HK1240233B (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
HK1240233A1 (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
JP2023524456A (ja) 担体への組込みに適したｃｄ３３リガンド
US20030171302A1 (en) Opioid derivative
BR112017011446B1 (pt) Composto, composição e uso dos mesmos
NZ732034B2 (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
RU2829816C1 (ru) Производное циннамида оленана, способ его получения и применение
WO2025199359A1 (en) Methods of modulating cdk7 and flt3 using fused bicyclic compounds
US20050222126A1 (en) Antiangiogenic compounds and an assay for inhibitors of cell invasion
CA2435633A1 (en) Antiangiogenic compounds and an assay for inhibitors of cell invasion
CN1283198A (zh) 细胞毒性的吡啶并吖啶类生物碱

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200408

R150 Certificate of patent or registration of utility model

Ref document number: 6689854

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees